Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond

By S. Lipton. Nature reviews. Drug discovery, 2006

920 citations recorded by the source corpus.

Subfields: Biochemistry, Cellular and Molecular Neuroscience, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/1bfed17975c539402d60536439fb5a8ddbf8f971

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biochemistry

1. E. Trushina
2. E. Tönnies

In Cellular and Molecular Neuroscience

1. E. Trushina
2. E. Tönnies
3. P. Lacor
4. P. Velasco
5. W. Klein
6. C. Parsons
7. A. Stöffler
8. W. Danysz

In Molecular Biology

1. E. Trushina
2. E. Tönnies

Citations in the corpus

• Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. (2007, background): “Rogawski and Wenk, 2003; Lipton, 2006; Wenk et al., 2006; Bullock, 2006).”
• Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease (2007, background): “Because the Alzheimer’s drug Namenda (memantine) is thought to function therapeutically as an openchannel blocker of NMDA receptors (Lipton, 2006) and NMDA receptors codistribute in hippocampal cultures with ADDLs, we tested whether memantine might exhibit efficacy in blocking ADDL-induced drebrin…”
• Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease (2017, background): “Importantly, memantine has greater affinity to non-synaptic NMDA receptors, which are implicated in excitotoxicity associated with the glutamate spillover and have distinctly different composition of receptor subunits [164, 165].”